Hi Dan,
The answers I have been getting from Xillix IR is that the biotech and small cap sectors have been out of favour for eons, and Xillix has felt a very strong impact from this fact.
I believe this has contributed to Xillix's present valuation, however I do not believe that the company has been doing a very good job in selling the technology to the investment community, and to the general public as well. We have a technology that can have a dramatic impact on detection and localization of different forms of cancers -- why has this not been a big story. Aside from a very positive, full length article in the Financial Post Magazine (September 1996 issue), I have heard very little about Xillix in the press. I find it difficult to comprehend the valuations we are seeing today -- there are strong fundamentals in that we have a strong cash position, continued developments in additional applications, a strong distribution partner, patents, etc, etc.
There is a difference between hyping, and promoting a company. I would like to see Xillix more proactive in getting its story out. It can't just rely on Olympus to do the promotion, the promotion has to stem from senior management and the board.
Laurie did mention that we could have a potentially strong fourth quarter. Perhaps things will start turning around in the new year.
By the way Dan, what was the program you saw featuring the CEO. Just curious. Thanks!
Garry |
